from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2fWRSiA on September 29, 2017 at 06:16PM
But the problems don’t end there, according to Harvard Medical School Epidemiologist and Lawyer Ameet Sarpatwari.
“There is a very aggressive lobby that is finding any and all means to thwart any reform to a system that has produced very lucrative profits,” Sarpatwari says. “Everything that’s coming out is being hit and hit hard — even stuff that’s common-sensical.”
Despite interests on behalf of big pharma and partisan back-and-forths among U.S. legislators, there are still a number of proposals in Congress aimed at curbing rising drug costs.